To assess the efficacy (response rate, complete and partial) of PF-03446962 given by IV infusion Day 1 of a 2 week cycle (14 days = 1 cycle) in patients with advanced malignant pleural mesothelioma and previously treated with cytotoxic therapy.~To assess the toxicity, safety and tolerability of PF-03446962.~To assess the duration of response or stable disease, stable disease rate, progression-free, median and overall survival rates.~To collect tissue and blood for banking and correlative science evaluation.
This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.